FDA
FDA Articles
Valeant Pharmaceuticals shares were down over 5% in premarket trading Monday after the FDA failed to approve the company's lotion intended to treat plaque psoriasis.
Published:
Last Updated:
Kellogg Co. (NYSE: K) announced on Thursday that it would be recalling roughly 1.3 million cases of its Honey Smack cereal due to a the potential for Salmonella contamination. The U.S. Food &...
Published:
Last Updated:
Nightstar Therapeutics PLC (NASDAQ: NITE) shares saw a massive gain on Thursday after the firm announced a crucial decision from the U.S. Food and Drug Administration (FDA). Essentially, the agency...
Published:
Last Updated:
Merck & Co., Inc. (NYSE: MRK) shares took a small step back on Thursday after the company announced a key approval from the U.S. Food and Drug Administration. The agency has now approved Keytruda...
Published:
Last Updated:
CRISPR Therapeutics shares saw a significant drop on Thursday morning after an announcement that the FDA placed a clinical hold on the Investigational New Drug Application (IND) for CTX001 for the...
Published:
Last Updated:
Pfizer announced early on Monday that it received a couple critical updates from the FDA related to its Xalkori (crizotinib).
Published:
Last Updated:
Amgen shares made a slight gain on Tuesday after it was announced that the FDA approved its treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture.
Published:
Last Updated:
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) shares dropped on Monday following a critical update from the U.S. Food and Drug Administration (FDA) on one of its subsidiaries. Essentially the agency...
Published:
Last Updated:
Amgen shares saw a nice bump after the FDA on Thursday approved its preventive treatment of migraine in adults.
Published:
Last Updated:
Evolus watched its shares come crashing down on Wednesday after the company announced that the FDA issued a Complete Response Letter for its treatment of glabellar lines, also known as frown lines,...
Published:
Last Updated:
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates in May.
Published:
Last Updated:
Portola Pharmaceuticals saw its shares soar on Friday after the firm announced that it had received an approval from the FDA.
Published:
Last Updated:
As we have said before, the FDA has the potential to make or break biopharma companies, and in this case Achaogen is feeling the burn.
Published:
Last Updated:
Epizyme shares tumbled on Tuesday after the FDA announced a partial clinical hold affecting new enrollment of patients in the firm's tazemetostat trials.
Published:
Last Updated:
Incyte and Eli Lilly will be under the microscope next week as the FDA will decide the fate of their rheumatoid arthritis treatment.
Published:
Last Updated: